Glaucoma Treatment Market Analysis

Glaucoma Treatment Market Analysis

Based on disease type, the glaucoma treatment market is segmented as open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment accounted for more than USD 4.5 billion in 2021. The growth of the segment is attributed to high prevalence of open angle glaucoma worldwide. For instance, as per the British Journal of Ophthalmology, POAG is the most common type of glaucoma in the UK that affects 2% of people older than 40 years and 10% of people older than 75 years. Moreover, growing usage of hypotensive drops to reduce intra ocular pressure is contributing to the overall segmental expansion.
 

Based on drug class, the glaucoma treatment market is categorized into prostaglandin analogs, beta blockers, adrenergic agonists, carbonic anhydrase inhibitors, and others. Prostaglandin analogs segment held more than 30% market share in 2021 owing to increasing accessibility and availability of ophthalmic medications worldwide. High adoption of prostaglandin analogs to reduce intraocular pressure with several benefits including once daily dosing effectivity, the enhanced recovery rate in glaucoma treatment will spur segmental demand. Furthermore, increasing demand for prostaglandin drugs in combination therapy is anticipated to offer enormous growth opportunities in the segment. Also, growing awareness about early glaucoma treatment along with rising patient population undergoing early glaucoma disease diagnosis will further boost the overall market statistics.
 

Based on distribution channel, the glaucoma treatment market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment garnered more than USD 3 billion in 2021. The segment is predicted to grow substantially over the analysis timeframe. The substantial growth is owing to high availability of products in settings for several types of glaucoma treatment. Also, patient preference towards hospital pharmacy for prescribed products helps in revenue generation. Furthermore, reimbursement policies and insurance cover provided for drug purchase in hospital settings will boost its market forecasts.
 

North America glaucoma treatment market is poised to grow at 3.4% CAGR over projected timeline. Increasing prevalence of several types of glaucoma in the region will accelerate the demand for glaucoma treatments. Growing awareness related to eye care and associated diagnosis and treatments will spur market size. Moreover, strong presence of key market players in the region that are involved in new drug development and product approvals will strengthen regional industry growth.